Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy

<b>Background/Objectives:</b> Type 2 diabetes mellitus (T2DM) and its macro- and microvascular complications are major health concerns with multiple factors, like advanced end glycation products (AGEs), in the background. AGEs induce long-lasting functional modification of the proteins a...

Full description

Bibliographic Details
Main Authors: Sára Csiha, Marcell Hernyák, Ágnes Molnár, Hajnalka Lőrincz, Mónika Katkó, György Paragh, Miklós Bodor, Mariann Harangi, Ferenc Sztanek, Eszter Berta
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Biomedicines
Subjects:
advanced glycation end products
AGEs
sRAGE
diabetic neuropathy
alpha lipoic acid
atherosclerosis
Online Access:https://www.mdpi.com/2227-9059/13/2/438

Internet

https://www.mdpi.com/2227-9059/13/2/438

Similar Items